GSK Flovent/Advair Diskus Needs More COPD Data; Serevent Cleared For COPD
Executive Summary
FDA is seeking additional efficacy data on GlaxoSmithKline's Flovent Diskus and Advair Diskus for chronic obstructive pulmonary disease before approving the products for the supplementary indication
You may also be interested in...
Pfizer/Boehringer Spiriva Launched At 30% Discount To Advair For COPD
Pfizer and Boehringer Ingelheim are launching the chronic obstructive pulmonary disease therapy Spiriva at a 30% discount to the average wholesale price of GlaxoSmithKline's Advair
Pfizer/Boehringer Spiriva Launched At 30% Discount To Advair For COPD
Pfizer and Boehringer Ingelheim are launching the chronic obstructive pulmonary disease therapy Spiriva at a 30% discount to the average wholesale price of GlaxoSmithKline's Advair
Pfizer/Boehringer Spiriva Clears FDA For COPD; Launch Set For Summer
Pfizer/Boehringer Ingelheim's marketing plan for Spiriva will emphasize the drug's long-term efficacy compared to other COPD therapies